nmpЖурнал им. Н.В. Склифосовского «Неотложная медицинская помощь»Russian Sklifosovsky Journal "Emergency Medical Care"2223-90222541-8017“N.V. Sklifosovsky Research Institute for Emergency Medicine”10.23934/2223-9022-2017-6-1-3-4nmp-342Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS OF LITERATUREАНТИБАКТЕРИАЛЬНАЯ ТЕРАПИЯ ГНОЙНО-СЕПТИЧЕСКИХ ОСЛОЖНЕНИЙ В УСЛОВИЯХ УСТОЙЧИВОСТИ ВОЗБУДИТЕЛЕЙ К  КАРБАПЕНЕМАМANTIBACTERIAL THERAPY OF SEPTIC COMPLICATIONS IN RESISTANCE OF PATHOGENS TO CARBAPENEMSЧерненькаяТ. В.ChernenkayaT. V.

кандидат медицинских наук, заведующая научной лабораторией клинической микробиологии,

Москва

Cand. Med. Sci., Head of the Scientific Laboratory,

Moscow

chernenkayat@rambler.ruГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского Департамента здравоохранения г. Москвы»РоссияN.V. Sklifosovsky Researh Institute for Emergency MedicineRussian Federation201729032017613440Copyright © Черненькая Т.В., 20172017Черненькая Т.В.Chernenkaya T.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jnmp.ru/jour/article/view/342

В настоящее время устойчивость грамотрицательных бактерий к карбапенемам приобретает глобальные масштабы. В случае развития заболеваний, вызванных такими возбудителями, отмечается неэффективность стандартных схем антибактериальной терапии. Следствие этого — значительное увеличение длительности госпитализации, затрат на лечение и летальности. В обзоре литературы представлены возможности антибактериальной терапии для лечения инфекций, вызванных резистентными к карбапенемам возбудителями.

Today, the resistance of Gram-negative bacteria to carbapenems becomes a global problem. Standard regimens of antibiotic treatments are noted to be ineffective in the development of diseases, caused by such pathogens, which resulted in a significant increase in hospital stay duration, cost of treatment and mortality rate. The review of literature describes therapeutic opportunities for treatment of diseases caused by pathogens resistant to carbapenems.

карбапенемырезистентностьантибиотикиAcinetobacter spp.Pseudomonas aeruginosaKlebsiella pneumoniacarbapenemsresistanceantibioticsAcinetobacter spp.Pseudomonas aeruginosaKlebsiella pneumoniaReferencesAntibiotics resistance ‘as big a risk as terrorism’ [Электронный ресурс]. URL: http://www.bbc.com/news/health-21737844.Antibiotics resistance ‘as big a risk as terrorism’. Available at: http://www.bbc.com/news/health-21737844. (Accessed 28 Febrary 2017).Блейзер М. Жизнь после антибиотиков: чем нам грозит устойчивость бактерий к антибиотикам и нарушение микрофлоры. М.: Изд-во Э, 2016. 240 с.Bleyzer M. Life after antibiotics: What we are facing resistance of bacteria to antibiotics and violation of the microflora. Moscow: Publisher E, 2016. 240 p. (In Russian).Jawetz E., Melnick J.L., Adelberg E.A. Review of medical microbiology. 17th ed. Upper Saddle River, NJ: Prentice Hall Inc., 1987. 595 p. (A Lange Medical Book).Jawetz E., Melnick J.L., Adelberg E.A. Review of medical microbiology. 17th ed. Upper Saddle River, NJ: Prentice Hall Inc., 1987. 595 p. (A Lange Medical Book).Lyon J.A. Imipenem/cilastatin: the first carbapenem antibiotic. Drug. Intell. Clin. Pharm. 1985; 19(12): 895–899. PMID: 3910385.Lyon J.A. Imipenem/cilastatin: the first carbapenem antibiotic. Drug Intell Clin Pharm. 1985; 19(12): 895–899. PMID: 3910385.Queenan A.M., Bush K. Carbapenemases: the versatile betalactamases. Clin. Microbiol. Rev. 2007; 20(3): 440–458. PMID: 23202428. DOI: 10.3233/ISB-2012-0443.Queenan A.M., Bush K. Carbapenemases: the versatile betalactamases. Clin Microbiol Rev. 2007; 20(3): 440–458. PMID: 23202428. DOI: 10.3233/ISB-2012-0443.Grundmann H., Livermore D.M., Giske C.G., et al. Carbapenem-nonsusceptible Enterobacteriacae in Europe: conclusions from a meeting of national experts [Электронный ресурс]. URL: // www.eurosurveillance.org/ViewArticle.aspx?Articleid=19711Grundmann H., Livermore D.M., Giske C.G., et al. Carbapenem-nonsusceptible Enterobacteriacae in Europe: conclusions from a meeting of national experts. Eurosurveillance. 2010; 15(46). Available at: www.eurosurveillance.org/ViewArticle.aspx?Articleid=19711 (Accessed 28 Febrary 2017).Tumbarello M., Viale P., Viscoli C., et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin. Infect. Dis. 2012; 55(7): 943–950. PMID: 22752516. DOI: 10.1093/cid/cis588.Tumbarello M., Viale P., Viscoli C., et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012; 55(7): 943–950. PMID: 22752516. DOI: 10.1093/cid/cis588.Senbayrak Akcay S., Inan A., Cevan S., et al. Gram-negative bacilli causing infections in an intensive care unit of a tertiary care hospital in Istanbul, Turkey. J. Infect. Dev. Ctries. 2014; 8(5): 597–604. PMID: 24820463. DOI: 10.3855/jidc.4277.Senbayrak Akcay S., Inan A., Cevan S., et al. Gram-negative bacilli causing infections in an intensive care unit of a tertiary care hospital in Istanbul, Turkey. J Infect Dev Ctries. 2014; 8(5): 597–604. PMID: 24820463. DOI: 10.3855/jidc.4277.Viehman J.A., Nguyen M.H., Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumanniiinfections. Drugs. 2014; 74(12): 1315–1333. PMID: 25091170. DOI: 10.1007/s40265-014-0267-8.Viehman J.A., Nguyen M.H., Doi Y. Treatment options for carbapenemresistant and extensively drug-resistant Acinetobacter baumanniiinfections. Drugs. 2014; 74(12): 1315–1333. PMID: 25091170. DOI: 10.1007/s40265-014-0267-8.Falagas M.E., Tansarli G.S., Karageorgopoulos D.E., Vardakas K.Z. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg. Infect. Dis. 2014; 20(7): 1170–1175. PMID: 24959688. DOI: 10.3201/eid2007.121004.Falagas M.E., Tansarli G.S., Karageorgopoulos D.E., Vardakas K.Z. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014; 20(7): 1170–1175. PMID: 24959688. DOI: 10.3201/eid2007.121004.Гаузе Г.Ф. Лекции по антибиотикам. 2-е изд. М.: Медгиз, 1953. 250 с.Gauze G.F. Lectures on antibiotics. 2nd ed. Moscow: Medgiz, 1953. 250 p.Walsh T.R., Toleman M.A., Poirel L., Nordmann P. Metallo-betalactamases: the quiet before the storm? Clin. Microb. Rev. 2005; 18(2): 306–325. PMID: 15831827. DOI: 10.1128/CMR.18.2.306-325.2005.Walsh T.R., Toleman M.A., Poirel L., Nordmann P. Metallo-betalactamases: the quiet before the storm? Clin Microb Rev. 2005; 18(2): 306–325. PMID: 15831827. DOI: 10.1128/CMR.18.2.306-325.2005.Bennett P.M. Integrons and gene cassettes: a genetic construction kit for bacteria. J. Antimicrob. Chemother. 1999; 43(1): 1–4. PMID: 10381094.Bennett P.M. Integrons and gene cassettes: a genetic construction kit for bacteria. J Antimicrob Chemother. 1999; 43(1): 1–4. PMID: 10381094Antimicrobial Resistance [Электронный ресурс]. URL: http://www.idsociety.org/10x20/Antimicrobial Resistance [Электронный ресурс]. URL: http://www.idsociety.org/10x20/FDA approves new antibacterial drug Zerbaxa. Fourth new antibacterial drug approved this year. [Электронный ресурс]. URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427534.htmFDA approves new antibacterial drug Zerbaxa. Fourth new antibacterial drug approved this year. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427534.htm (Accessed 28 Febrary 2017).FDA approves new antibacterial drug Avycaz. [Электронный ресурс]. URL: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm435629.htmFDA approves new antibacterial drug Avycaz. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm435629.htm (Accessed 28 Febrary 2017).Cho J.C., Fiorenza M.A., Estrada S.J. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination. Pharmacotherapy. 2015; 35(7): 701–715. PMID: 26133315. DOI: 10.1002/phar.1609.Cho J.C., Fiorenza M.A., Estrada S.J. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination. Pharmacotherapy. 2015; 35(7): 701–715. PMID:26133315. DOI: 10.1002/phar.1609.Zhanel G.G., Lawson C.D., Adam H., et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013; 73(2): 159–177. PMID: 26948862. DOI: 10.1016/j.clinthera.2016.01.018.Zhanel G.G., Lawson C.D., Adam H., et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013; 73(2): 159–177. PMID: 26948862. DOI: 10.1016/j.clinthera.2016.01.018.Karpiuk I., Tyski S. Looking for new preparations for antibacterial therapy. IV. New antimicrobial agents from the aminoglycoside, macrolide and tetracycline groups in clinical trials. Przegl. Epidemiol. 2015; 69(4): 723–729, 865–870. PMID: 27139351.Karpiuk I., Tyski S. Looking for new preparations for antibacterial therapy. IV. New antimicrobial agents from the aminoglycoside, macrolide and tetracycline groups in clinical trials. Przegl. Epidemiol. 2015; 69(4): 723–729, 865–870. PMID: 27139351.Karpiuk I., Tyski S. Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trials. Przegl. Epidemiol. 2013; 67(3): 455–460, 557–561. PMID: 24340560.Karpiuk I., Tyski S. Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trials. Przegl. Epidemiol. 2013; 67(3): 455–460,557–561. PMID: 24340560.Lapuebla A., Abdallah M., Olafisoye O., et al. Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City. Antimicrob. Agents Chemother. 2015; 59(8): 4856–4860. PMID: 26033723. DOI: 10.1128/AAC.00843-15.Lapuebla A., Abdallah M., Olafisoye O., et al. Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City. Antimicrob Agents Chemother. 2015; 59(8): 4856–4860. PMID: 26033723. DOI: 10.1128/AAC.00843-15.Bhalodi A.A., Crandon J.L., Williams G., Nicolau D.P. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model. Int. J. Antimicrob. Agents. 2014; 44(6): 508–513. PMID: 25278330. DOI: 10.1016/j.ijantimicag.2014.07.021.Bhalodi A.A., Crandon J.L., Williams G., Nicolau D.P. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model. Int J Antimicrob. Agents. 2014; 44(6): 508–513. PMID: 25278330. DOI: 10.1016/j.ijantimicag.2014.07.021.Livermore D.M., Warner M., Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2013; 68(10): 2286–2290. PMID: 23696619. DOI: 10.1093/jac/dkt178.Livermore D.M., Warner M., Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013; 68(10): 2286–2290. PMID: 23696619. DOI: 10.1093/jac/dkt178.Tumbarello M., Trecarichi E.M., De Rosa F.G., et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J. Antimicrob. Chemother. 2015; 70(7): 2133–2143. PMID: 25900159. DOI: 10.1093/jac/dkv086.Tumbarello M., Trecarichi E.M., De Rosa F.G., et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015; 70(7): 2133–2143. PMID: 25900159. DOI: 10.1093/jac/dkv086.Levy Hara G., Gould I., Endimiani A., et al. Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group. J. Chemother. 2013; 25(3): 129–140. PMID: 23783137. DOI: 10.1179/1973947812Y.000 0000062.Levy Hara G., Gould I., Endimiani A., et al. Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group. J Chemother. 2013; 25(3): 129–140. PMID: 23783137. DOI: 10.1179/1973947812Y.0000000062.Bulik C.C., Nicolau D.P. Double-Carbapenem Therapy for CarbapenemaseProducing Klebsiella pneumonia. Antimicrob. Agents Chemother. 2011; 55(6): 3002–3004. PMID: 21422205. DOI: 10.1128/AAC.01420-10.Bulik C.C., Nicolau D.P. Double-Carbapenem. Therapy for Carbapenemase-Producing Klebsiella pneumonia. Antimicrob Agents Chemother. 2011; 55(6): 3002–3004. PMID: 21422205. DOI: 10.1128/AAC.01420-10.Giamarellou H., Galani L., Baziaka F., Karaiskos I. Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumonia. Antimicrob. Agents Chemother. 2013; 57(5): 2388–2390. PMID: 23439635. DOI: 10.1128/AAC.02399-12.Giamarellou H., Galani L., Baziaka F., Karaiskos I. Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumonia. Antimicrob Agents Chemother. 2013; 57(5): 2388–2390. PMID: 23439635. DOI: 10.1128/AAC.02399-12.Oliva A., Mascellino M.T., Cipolla A., et al. Therapeutic strategy for pandrug-resistant Klebsiella pneumonia severe infections: shortcourse treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen. Int. J. Infect. Dis. 2015; 33: 132–134. PMID: 25597275. DOI: 10.1016/j.ijid.2015.01.011.Oliva A., Mascellino M.T., Cipolla A., et al. Therapeutic strategy for pandrug-resistant Klebsiella pneumonia severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen. Int J Infect Dis. 2015; 33: 132–134. PMID: 25597275. DOI: 10.1016/j.ijid.2015.01.011.Marco F., Dowzicky M.J. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004–2014. J. Glob. Antimicrob. Resist. 2016; 6: 50–56. PMID: 27530839. DOI: 10.1016/j.jgar.2016.02.005.Marco F., Dowzicky M.J. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004–2014. J Glob Antimicrob Resist. 2016; 6: 50–56. PMID: 27530839. DOI: 10.1016/j.jgar.2016.02.005.FDA Drug Safety Podcast: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning [Электронный ресурс]. URL: http://www.fda.gov/drugs/drugsafety/drugsafetypodcasts/ucm370626.htmFDA Drug Safety Podcast: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. Available at: http://www.fda.gov/drugs/drugsafety/drugsafetypodcasts/ucm370626.htm (Accessed 28 Febrary 2017).Maseda E., Suárez-de-la-Rica A., Anillo V., et al. A practice-based observational study identifying factors associated with the use of highdose tigecycline in the treatment of secondary peritonitis in severely ill patients. Rev. Esp. Quimioter. 2015: 28(1): 47–53. PMID: 25690145.Maseda E., Suárez-de-la-Rica A., Anillo V., et al. A practice-based observational study identifying factors associated with the use of highdose tigecycline in the treatment of secondary peritonitis in severely ill patients. Rev Esp Quimioter. 2015: 28(1): 47–53. PMID: 25690145.Ni W., Han Y., Liu J., et al. Tigecycline Treatment for CarbapenemResistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2016; 95(11): e3126. PMID: 26986165. DOI: 10.1097/MD.0000000000003126.Ni W., Han Y., Liu J., et al. Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2016; 95(11): e3126. PMID: 26986165. DOI: 10.1097/MD.0000000000003126.Qureshi Z.A., Syed A., Clarke L.G., et al. Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria. Antimicrob. Agents Chemother. 2014; 58(6): 3100–3104. PMID: 24637691. DOI: 10.1128/AAC.02445-13.Qureshi Z.A., Syed A., Clarke L.G., et al. Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria. Antimicrob Agents Chemother. 2014; 58(6): 3100–3104. PMID: 24637691. DOI: 10.1128/AAC.02445-13.Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 2008; 21(3): 538–582. PMID: 18625687. DOI: 10.1128/CMR.00058-07.Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008; 21(3): 538–582. PMID: 18625687. DOI: 10.1128/CMR.00058-07.Chu H., Zhao L., Wang M., et al. Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and metaanalysis. Braz. J. Infect. Dis. 2013; 17(4): 389–394. PMID: 23602463. DOI: 10.1016/j.bjid.2012.10.029.Chu H., Zhao L., Wang M., et al. Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis. Braz J Infect Dis. 2013; 17(4): 389–394. PMID: 23602463. DOI: 10.1016/j.bjid.2012.10.029.Навашин С.М., Фомина И.П. Рациональная антибиотикотерапия. М.: Медицина, 1982. 495 с.Navashin S.M., Fomina I.P. Rational antibiotic therapy. Moscow: Meditsina Publ., 1982. 495 p. (In Russian).Drapeau C.M.J., Grilli E., Petrosillo N. Rifampicin combined regimens for Gram-negative infections: data from the literature. Int. J. Antimicrob. Agents. 2010; 35(1): 39–44. PMID: 19815392. DOI: 10.1016/j.ijantimicag.2009.08.011.Drapeau C.M.J., Grilli E., Petrosillo N. Rifampicin combined regimens for Gram-negative infections: data from the literature. Int J Antimicrob Agents. 2010; 35(1): 39–44. PMID: 19815392. DOI: 10.1016/j.ijantimicag.2009.08.011.Durante-Mangoni E., Signoriello G., Andini R., et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin. Infect. Dis. 2013; 57(3): 349–358. PMID: 23616495. DOI: 10.1093/cid/cit253.Durante-Mangoni E., Signoriello G., Andini R., et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013; 57(3): 349–358. PMID: 23616495. DOI: 10.1093/cid/cit253.Bergen P.J., Landersdorfer C.B., Zhang J., et al. Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new? Diagn. Microbiol. Infect. Dis. 2012; 74(3): 213–223. PMID: 22959816. DOI: 10.1016/j.diagmicrobio.2012.07.010.Bergen P.J., Landersdorfer C.B., Zhang J., et al. Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new? Diagn. Microbiol. Infect. Dis. 2012; 74(3): 213–223. PMID: 22959816. DOI: 10.1016/j.diagmicrobio.2012.07.010.Hu Y., Li L., Li W., et al. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a metaanalysis of retrospective and prospective studies. Int. J. Antimicrob. Agents. 2013; 42(6): 492–496. PMID: 24139926. DOI: 10.1016/j.ijantimicag.2013.09.002.Hu Y., Li L., Li W., et al. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies. Int J Antimicrob Agents. 2013; 42(6): 492–496. PMID: 24139926. DOI: 10.1016/j.ijantimicag.2013.09.002.Bergen P.J., Bulman Z.P., Landersdorfer C.B., et al. Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. Infect. Dis. Ther. 2015; 4(4): 391–415. PMID: 26645096. DOI: 10.1007/s40121-015-0093-7.Bergen P.J., Bulman Z.P., Landersdorfer C.B., et al. Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. Infect Dis Ther. 2015; 4(4): 391–415. PMID: 26645096. DOI: 10.1007/s40121-015-0093-7.Galani I., Orlandou K., Moraitou H., et al. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii. Int. J. Antimicrob. Agents. 2014; 43(4): 370–374. PMID: 24560919. DOI: 10.1016/j.ijantimicag.2013.12.010.Galani I., Orlandou K., Moraitou H., et al. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2014; 43(4): 370–374. PMID: 24560919. DOI: 10.1016/j.ijantimicag.2013.12.010.Lu Q., Luo R., Bodin L., et al. Nebulized Antibiotics Study Group. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology. 2012; 117(6): 1335–1347. PMID: 23132092. DOI: 10.1097/ALN.0b013e31827515de.Lu Q., Luo R., Bodin L., et al. Nebulized Antibiotics Study Group. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology. 2012; 117(6): 1335–1347. PMID: 23132092. DOI: 10.1097/ALN.0b013e31827515de.Karaiskos I., Galani L., Baziaka F., Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrugresistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int. J. Antimicrob. Agents. 2013; 41(6): 499–508. PMID: 23507414. DOI: 10.1016/j.ijantimicag.2013.02.006.Karaiskos I., Galani L., Baziaka F., Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrugresistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents. 2013; 41(6): 499–508. PMID: 23507414. DOI: 10.1016/j.ijantimicag.2013.02.006.Falagas M.E., Vouloumanou E.K., Samonis G., Vardakas K.Z. Fosfomycin. Clin. Microbiol. Rev. 2016; 29(2): 321–347. PMID: 26960938. DOI: 10.1128/CMR.00068-15.Falagas M.E., Vouloumanou E.K., Samonis G., Vardakas K.Z. Fosfomycin. Clin Microbio. Rev. 2016; 29(2): 321–347. PMID: 26960938. DOI: 10.1128/CMR.00068-15.Evren E., Azap O.K., Colakoglu S., Arslan H. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Diagn. Microbiol. Infect. Dis. 2013; 76(3): 335–338. PMID: 23726147. DOI: 10.1016/j.diagmicrobio.2013.04.004.Evren E., Azap O.K., Colakoglu S., Arslan H. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Diagn Microbiol Infect Dis. 2013; 76(3): 335–338. PMID: 23726147. DOI: 10.1016/j.diagmicrobio.2013.04.004.Nitzan O., Kennes Y., Colodner R., et al. Chloramphenicol use and susceptibility patterns in Israel: a national survey. Isr. Med. Assoc. J. 2015; 17(1): 27–31. PMID: 25739173.Nitzan O., Kennes Y., Colodner R., et al. Chloramphenicol use and susceptibility patterns in Israel: a national survey. Isr Med Assoc J. 2015; 17(1): 27–31. PMID: 25739173.Nitzan O., Suponitzky U., Kennes Y., et al. Is chloramphenicol making a comeback? Isr. Med. Assoc. J. 2010; 12(6): 371–374. PMID: 20928993.Nitzan O., Suponitzky U., Kennes Y., et al. Is chloramphenicol making a comeback? Isr Med Assoc J. 2010; 12(6): 371–374. PMID: 20928993.Sood S. Chloramphenicol — A Potent Armament Against Multi-Drug Resistant (MDR) Gram Negative Bacilli? J. Clin. Diagn. Res. 2016; 10(2): DC01–3. PMID: 27042458. DOI: 10.7860/JCDR/2016/14989.7167.Sood S. Chloramphenicol — A Potent Armament Against Multi-Drug Resistant (MDR) Gram Negative Bacilli? J Clin Diagn Res. 2016; 10(2): DC01-3. PMID: 27042458. DOI: 10.7860/JCDR/2016/14989.7167.Eliakim-Raz N., Lador A., Leibovici-Weissman Y., et al. Efficacy and safety of chloramphenicol: joining the revival of old antibiotics? Systematic review and meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 2015; 70(4): 979–996. PMID: 25583746. DOI: 10.1093/jac/dku530.Eliakim-Raz N., Lador A., Leibovici-Weissman Y., et al. Efficacy and safety of chloramphenicol: joining the revival of old antibiotics? Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2015; 70(4): 979–996. PMID: 25583746. DOI: 10.1093/jac/dku530.Богомолова Н.С., Большаков Л.В., Кузнецова С.М. Проблема лечения гнойно-воспалительных осложнений, обусловленных Acinetobacter. Анестезиология и реаниматология. 2014; (1): 26–32.Bogomolova N.S., Bol’shakov L.V., Kuznetsova S.M. Problem of treatment for pyo-inflammatory complications caused by Acinetobacter. Anesteziologiya i reanimatologiya. 2014; (1): 26–32. (In Russian).Падейская Е.Н. Антибактериальный препарат Диоксидин: особенности биологического действия и значение в терапии различных форм гнойной инфекции. Инфекции и антимикробная терапия. 2001; (5): 150–155.Padeyskaya E.N. Antibacterial drug Dioxidine: particular biological activities and importance in the treatment of various forms of purulent infection. 2001; (5): 150–155. (In Russian).Попов Д.А., Анучина Н.М., Терентьев А.А. и др. Диоксидин: антимикробная активность и перспективы клинического применения на современном этапе // Антибиотики и химиотерапия. 2013; 58(3–4): 37–42.Popov D.A., Anuchina N.M., Terent’ev A.A., et al. Dioxidin: Antimicrobial Activity and Prospects of Its Clinical Use at Present. Antibiotiki i khimioterapiya. 2013; 58(3–4): 37–42. (In Russian).Федянин С.Д., Шилин В.Е. Определение минимальной подавляющей концентрации диоксидина для ведущих возбудителей хирургических инфекций. Вестник Витебского государственного медицинского университета. 2015; 14(5): 73–77.Fedyanin S.D., Shilin V.E. The determination of the minimum inhibitory concentration of Dioxydin for the leading causative agents of surgical infections. Vestnik Vitebskogo gosudarstvennogo meditsinskogo universiteta. 2015; 14(5): 73–77. (In Russian).Савельев В.С., Гельфанд Б.Р., Яковлев С.В. (ред.) Стратегия и тактика применения антимикробных средств в лечебных учреждениях России. Российские национальные рекомендации / под ред. М., 2012. 96 с.Savel’ev V.S., Gel’fand B.R., Yakovlev S.V., eds. Strategy and tactics of application of antimicrobial agents in medical institutions of Russia. Moscow, 2012. 96 p. (In Russian).Сухорукова М.В., Эйдельштейн М.В., Склеенова Е.Ю. и др. Антибиотикорезистентность нозокомиальных штаммов Enterobacteriaceae в стационарах России: результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011–2012 гг. Клиническая микробиология и антимикробная химиотерапия. 2014: (4): 254–265.Sukhorukova M.V., Eydel’shteyn M.V., Skleenova E.Yu., et al. Antimicrobial Resistance of Nosocomial Enterobacteriaceae Isolates in Russia: Results of National Multicenter Surveillance Study “MARATHON” 2011–2012. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2014; (4): 254–265. (In Russian).Сухорукова М.В., Эйдельштейн М.В., Склеенова Е.Ю. и др. Антибиотикорезистентность нозокомиальных штаммов Pseudomonas aeruginosa в стационарах России: результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011–2012 гг. Клиническая микробиология и антимикробная химиотерапия.2014: (4): 273–279.Sukhorukova M.V., Eydel’shteyn M.V., Skleenova E.Yu., et al. Antimicrobial Resistance of Nosocomial Pseudomonas aeruginosa Isolates in Russia: Results of National Multicenter Surveillance Study “MARATHON” 2011–2012. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2014; (4): 273–279. (In Russian).Сухорукова М.В., Эйдельштейн М.В., Склеенова Е.Ю. и др. Антибиотикорезистентность нозокомиальных штаммов Acinetobacter spp. в стационарах России: результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011–2012 гг. Клиническая микробиология и антимикробная химиотерапия. 2014: (4): 266–272.Sukhorukova M.V., Eydel’shteyn M.V., Skleenova E.Yu., et al. Antimicrobial Resistance of Nosocomial Acinetobacter spp. Isolates in Russia: Results of National Multicenter Surveillance Study “MARATHON” 2011–2012. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2014: (4): 266–272. (In Russian).Doi Y., Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides // Clin. Infect. Dis. 2007: 45(1): 88–94.Doi Y., Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis. 2007; 45(1): 88–94.Ермольева З.В. (ред.) Антибиотики: экспериментально-клиническое изучение. М.: Медгиз, 1959. 434 с.Ermol’eva Z.V., ed. Antibiotics: experimental clinical study. Moscow: Medgiz, 1959. 434 p. (In Russian).

The authors declare that there are no conflicts of interest present.